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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT 
• Thiazide diuretics have long been demonstrated to be effective in lowering the 
risk of cardiovascular events by reducing blood pressure.  
• In the UK, the thiazide bendroflumethiazide and the thiazide-like indapamide are 
the most prescribed diuretics for hypertension treatment.  
• However, the comparative effectiveness of these two drugs is unclear. 
 
 
WHAT THIS STUDY ADDS 
 
• This review highlights a lack of studies on comparative efficacy of monotherapy 
with bendroflumethiazide versus indapamide on mortality, cardiovascular 
outcomes, blood pressure, need for intensification of treatment and treatment 
withdrawal. 
• This review shows a lack of evidence of superiority of one drug over the other.  
• There is a clear need for new studies directly comparing the effect of these drugs 
on the outcomes of interest. 
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Abstract 
Aims  
The aims were to compare the efficacy of monotherapy with bendroflumethiazide versus 
indapamide on mortality, cardiovascular outcomes, blood pressure, need for 
intensification of treatment and treatment withdrawal. 
Methods 
Two authors independently screened results of literature search, assessed the risk of bias 
and extracted relevant data. Randomized clinical trials of hypertensive patients of at least 
one-year duration were included. When there was disagreement, a third reviewer was 
consulted. Risk ratio (RR) and mean differences were used as measures of effect. 
Results 
Two trials comparing bendroflumethiazide against placebo, one comparing indapamide 
with placebo and three short duration trials directly comparing indapamide and 
bendroflumethiazide were included. No statistically significant difference was found 
between indapamide and bendroflumethiazide for all deaths (RR 0.82; 95% Confidence 
Interval (CI) 0.57-1.18), cardiovascular deaths (RR 0.82; 95%CI 0.55-1.20), non-
cardiovascular deaths (0.81; 95%CI 0.54-1.22), coronary events (RR 0.73; 95%CI 0.30-
1.79) or all cardiovascular events (RR 0.89; 95%CI 0.67-1.18). Indapamide performed 
worse for stroke (RR 2.21; 95%CI 1.19-4.11), even though a reduction in RR compared 
to placebo was observed in both groups. There was no statistically or clinically significant 
difference between indapamide and bendroflumethiazide in blood pressure reduction 
(mean absolute difference <1mmHg). 
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Conclusion 
This review highlights a lack of studies to answer the review question but also a lack of 
evidence of superiority of one drug over the other. Therefore, there is a clear need for 
new studies directly comparing the effect of these drugs on the outcomes of interest. 
Key words: 
Systematic review; hypertension; bendroflumethiazide; indapamide; cardiovascular; 
mortality; thiazide diuretics;   
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Introduction 
High blood pressure is one of the most important preventable causes of premature 
cardiovascular morbidity and mortality worldwide. World Health Organization (WHO) 
estimates the global prevalence in adults aged 25 years and over is around 40%. Raised 
blood pressure is estimated to cause 7.5 million deaths annually, about 12.8% of the total 
of all deaths. Moreover, hypertension increases the risk of developing coronary artery 
disease, stroke, heart failure, peripheral vascular disease, vision loss, chronic kidney 
disease, cognitive decline and early death.1 Treating hypertension reduces 
cardiovascular disease risk and the risk of death from cardiovascular causes.2 Thiazide 
diuretics are a class of antihypertensive medications launched in the 1950s and have long 
demonstrated effectiveness in reducing blood pressure and the risk of cardiovascular 
events.3 A recent Cochrane systematic review of first line drugs for hypertension 
concluded that “low-dose thiazides should be the first-choice drug in most patients with 
elevated blood pressure” due to the evidence of reduced mortality and morbidity such as 
stroke, heart attack and heart failure.4 Usually prescribed as first-line or second-line drug, 
alone or combined with drugs from other classes, 5,6 diuretics are classified into thiazides 
and thiazide-like diuretics.7 The most recent National Institute for Health and Clinical 
Excellence (NICE) guidelines for the management of hypertension published in 2011 8 
and evidence updated in 2013 9 specified that if “… a diuretic is required”, “… a thiazide-
like diuretic, such as chlortalidone (12.5 mg–25 mg once daily) or indapamide (2.5 mg 
once daily)” should be chosen … “in preference to a conventional thiazide diuretic such 
as bendroflumethiazide or hydrochlorthiazide”. However, there has been debate around 
whether these guidelines were supported by evidence.10 The existing systematic reviews 
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and meta-analyses focussed on efficacy of blood-pressure lowering 11,12,13,14,15 rather than 
long-term outcomes.16,17,18  
The primary objective of the present review was to compare efficacy of monotherapy with 
the thiazide diuretic bendroflumethiazide versus the thiazide-like diuretic indapamide as 
first-line in the treatment of primary hypertension on mortality and cardiovascular 
outcomes. The secondary objective was to compare the effect of these two 
monotherapies on secondary outcomes such as blood pressure lowering, the need for 
intensification of treatment and medication discontinuation. 
Methods 
The protocol for this review was registered with the international prospective register of 
systematic reviews (PROSPERO)19, registration number CRD42017067109. PRISMA 
guidelines 20 were followed for conducting and reporting of this review.  
Literature search strategy 
Literature search was performed from 2008 to April 2018 using the search strategy of 
Wright and Musini (2009) 4 and the NICE guidelines update 2013 9 modified to focus on 
indapamide and bendroflumethiazide. MEDLINE, EMBASE, CINAHL (using NHS 
Education for Scotland The Knowledge Network), the Cochrane Library (Cochrane 
Database of Systematic Reviews, Cochrane Central Register of Controlled Trials 
(CENTRAL), Cochrane Methodology Register), Health Technology Assessment 
Database, ClinicalTrials.gov, EU Clinical Trials Register and Google Scholar were 
searched. In addition, two high-impact peer reviewed journals appropriate for this review, 
British Journal of Clinical Pharmacology and the European Heart Journal, were hand 
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searched for the past five years.  References of the relevant published papers were also 
searched to help identify additional trials. Only publications in English language were 
included in this review. 
Inclusion and exclusion criteria 
Randomized controlled trials of adults with primary hypertension with at least one year 
follow up were included. Studies reporting monotherapy with bendroflumethiazide or 
indapamide were included where the comparator group was either a placebo or another 
drug. Supplemental medication with other drug classes were allowed as stepped-care 
therapy. It was assumed that these supplemental drugs did not systematically interact to 
affect the occurrence of the outcomes studied.  
Data extraction 
Two reviewers independently screened the title and the abstract of each study meeting 
the inclusion criteria. If disagreements occurred between the two reviewers, a third 
reviewer was consulted. For eligible studies, data extraction was performed by two 
reviewers independently using a specially designed data collection form. Disagreements 
were resolved after discussion with two other reviewers. The values of mean change from 
baseline in blood pressure at one year follow up and standard deviation were obtained 
from Wright and Musini (2009) 4 . Authors of studies were contacted, where the required 
information was clearly available but was not reported in the manuscript.  
Outcomes 
The primary outcomes considered were total mortality and cardiovascular outcomes such 
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as stroke, myocardial infarction, congestive heart failure and cardiovascular death. The 
secondary outcomes were adverse events, need for intensification of treatment, 
withdrawals and blood pressure lowering. Only published information was used in this 
review. 
Risk of bias in the included studies 
The Cochrane Collaboration’s tool for assessing risk of bias 21 was used to assess quality 
in the included studies. Items of methodological quality assessed were: method used to 
randomize participants, whether randomization was completed in an appropriate and 
blinded manner; whether participants, providers, outcome assessors, or a combination of 
these were blinded to assigned therapy; whether the control group received a placebo or 
no treatment; percent of participants who did not complete follow-up (drop-outs); percent 
of participants not on assigned active or placebo therapy at study completion; selective 
reporting of outcomes. Two reviewers conducted the assessment independently. If 
disagreement occurred, a third reviewer was consulted. The results were compared with 
those reported by Musini et al.22,23 
Data analysis 
Network meta-analysis was conducted using STATA 15 for Windows (2017). All analysis 
were intention-to-treat. Indirect comparisons were made using indirect STATA 
command.24 Graphical tools 25 were used as appropriate. Evidence was graded using 
approach of the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) 26 working group using GRADEpro.27  
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Results 
Search results 
The search resulted in 1878 publications (Figure 1). After the removal of duplicates and 
1418 irrelevant papers and having found additional 26 papers from hand searching the 
references of published papers, 128 full text papers were considered further. Reasons for 
exclusion of 112 articles are shown in Figure 1. Reviews, meta-analyses, commentaries, 
editorial and protocols were published in 52 articles, while 60 articles contained 
information from 53 individual studies. The most common reason for study exclusion was 
duration of treatment (<1 year) (n=22) followed by combination therapy (n=13) and trials 
not being a trial of hypertension (n=12). Other excluded studies were observational 
studies (n= 3), single arm trials (n= 3), not studies of bendroflumethiazide or indapamide 
(n= 5) or studies where exposure was any thiazide diuretic (n= 4).  
Three further studies (HYVET Pilot 28; DIME29 and HAPPHY 30) were excluded because 
the participating centres within each study were given a choice of type of thiazide diuretics 
depending on drug availability, but the published manuscripts did not report the results by 
type of drug. When contacted, authors or funders either did not reply, could not provide 
the information required or could not make the original datasets available for data 
analysis. Therefore, three studies reported in seventeen papers were included in this 
review. 31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47 
Because no studies of a direct comparison between indapamide and bendroflumethiazide 
for long-term outcome were found, we included three studies of short term follow up with 
blood pressure as an outcome.48,49,50  
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Description of the included studies and study participants 
Two studies were conducted in the United Kingdom 31,33 and one study was a multicentre 
clinical trial 42  (Table 1). They were published between 1973 and 2008. Study size ranged 
from 116 to 17,354 participants, and females comprised between 48% and 60%. Two 
studies included participants of mean age around 50-55 years, while in one study 42 the 
mean age of participants was 84 years. In two studies participants were followed up 
annually for 5 years 33,42 and one study followed the participants up to 18 months.31  
All studies had pharmaceutical industry sponsorship. Participants were recruited from a 
variety of sources, such as surveys of random samples of general population, hospitals 
and primary care (Table 2). Mild, moderate and persistent hypertension was used as 
inclusion criteria, and there was variation in the method of blood pressure measurement 
(Table 2). Two studies investigated Bendroflumethiazide 31,33 and one study investigated 
indapamide 42(Table 3). All three trials used placebo as a comparison and one study also 
used propranolol.33 Doses of all medications varied, and one study 31 did not specify the 
dose. All studies permitted additional medication at the discretion of physician or trial 
investigators (Table 3). Three short-term outcome studies directly comparing indapamide 
and bendroflumethiazide are described in Appendix 4. They were conducted in 1981 48,49 
and 2006 50, each included less than 30 participants with follow up between 4 and 16 
weeks.  
Definition of outcome 
Table 4 shows the availability of data on primary and secondary outcomes. Two trials  
33,42 had all primary outcomes data available, while the cause of death was missing for 
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two participants in the placebo group in Barraclough et al.31 All studies reported 
withdrawals for medical reasons, however the reported reasons differed between studies. 
For example, Barraclough et al 31 participants in the placebo group with diastolic blood 
pressure >130mmHg were withdrawn by design. There were insufficient data for other 
secondary outcomes such as additional medication, while data on diastolic blood 
pressure were reported in all studies and information on systolic blood pressure was 
available in two studies.33,42 
Risk of bias in the included studies 
Table 5 shows results of the assessment of risk of bias in each of the included studies. 
Two studies31,33 did not satisfy criteria for blinding and data completeness, two studies 
were not free of selective reporting31,42 one trial had inadequate allocation concealment 
and in one study42 random sequence generation was unclear. Appendix 5 shows results 
of the assessment of risk of bias in each of the three short-term outcome studies directly 
comparing indapamide and bendroflumethiazide. All three studies had high risk of bias.  
Effects of interventions 
Appendix 1 shows the data extracted for each outcome and effect of intervention for each 
study compared to placebo. In addition, Appendix 2 shows a forest plot by outcome for 
each study. Appendix 3 illustrates the network pattern, and Appendix 1 presents results 
of the indirect comparison of indapamide versus bendroflumethiazide. There was no 
statistically significant difference between indapamide and bendroflumethiazide on all 
deaths (indirect RR 0.82; 95% CI 0.57, 1.18), cardiovascular death (indirect RR 0.82; 95% 
CI 0.55, 1.20), non-cardiovascular death (indirect RR 0.81; 95% CI 0.54, 1.22), coronary 
events (indirect RR 0.73; 95% CI 0.30, 1.79) or all cardiovascular events (indirect RR 
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0.89; 95% CI 0.67, 1.18). However, whilst indapamide showed a reduction in risk for these 
outcomes compared to placebo, bendroflumethiazide did not show a difference compared 
to placebo for these outcomes except for all cardiovascular events combined (Appendix 
1, 2). Indapamide performed worse for the outcome of stroke and withdrawals for medical 
reasons (indirect RR 2.21; 95% CI 1.19, 4.11 and RR 1.23; 95% CI 1.07, 1.40, 
respectively). However, there was a reduction in RR compared to placebo in both of these 
groups except for withdrawals for medical reasons in the indapamide group (RR 0.98; 
95% CI 0.89, 1.07) (Appendix 1,2).  
Significant long-term reductions in blood pressure from baseline, in comparison to 
placebo, were reported in all studies. There were no statistically or clinically significant 
difference between indapamide and bendroflumethiazide (mean difference in reduction 
from baseline 0.94; 95% CI -1.45, 2.25 and 0.88 95% CI -0.19, 1.95 mmHg) in systolic 
and diastolic blood pressure respectively (Appendix 1,2). Appendix 6 shows data 
extracted for systolic and diastolic blood pressure for each study of the direct comparison 
between indapamide and bendroflumethiazide, while Appendix 7 shows a forest plot and 
summary effects. There was no statistically or clinically significant difference between 
indapamide and bendroflumethiazide (mean difference -0.26; 95% CI -0.79, 0.27 and -
0.40 95% CI --0.93, 0.14 mmHg) for systolic and diastolic blood pressure respectively 
(Appendix 7). 
There were only three studies included in meta-analysis of long-term outcomes and three 
studies of short-term blood pressure reduction. Appendix 8 shows funnel plots for these 
studies. There did not appear to be any evidence of publication bias for short term 
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outcomes as the figure for both types of blood pressure were symmetrical. However, this 
was less clear in case of indirect comparisons. 
Overall evidence 
Evidence was graded either as moderate or low (Tables 6 and 7).  
Discussion 
Bendroflumethiazide and indapamide are the most frequently prescribed diuretics for 
hypertension treatment in the UK.51 This is the first systematic review to directly compare 
indapamide and bendroflumethiazide. It demonstrates the lack of evidence on 
comparative effectiveness of these drugs on mortality and cardiovascular outcomes such 
as stroke and myocardial infarction, as only three eligible studies were available for 
analysis of these long-term outcomes, and none were studies of direct comparison. Three 
small studies of direct comparison were prone to bias, with low overall GRADE evidence.  
A meta-analysis of thiazide-like diuretics versus thiazide-type diuretics which included 
twelve studies comparing indapamide or chlorthalidone versus hydrochlorothiazide 
suggested that thiazide-like diuretics further reduce both systolic and diastolic BP (mean 
-5.59 mmHg 95% CI -5.69, -5.49 and -1.98 95% CI -3.29, -0.66, respectively.52  
A network meta-analyses that aimed to summarise the evidence on efficacy of 
antihypertensive therapies53 included 42 clinical trials randomised to seven types of 
treatment. Treatments considered were placebo, untreated, or usual care: low-dose 
diuretics; β-blockers; angiotensin-converting-enzyme (ACE) inhibitors; Angiotensin II 
receptor blockers (ARBs); Calcium channel blockers (CCBs); and α-blockers. This meta-
analysis showed that low-dose diuretics were the most effective first-line treatment for 
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preventing the occurrence of cardiovascular disease morbidity and mortality compared to 
other treatments. However, the low-dose diuretic therapies were usually the equivalent of 
12.5 to 25 mg per day of chlorthalidone or hydrochlorothiazide.  
Whilst only a limited number of studies were included in the present review, its strengths 
included having a pre-defined protocol and it followed current guidelines and statistical 
techniques. Every effort was made to find relevant studies, and multiple sources were 
searched. The search strategy was similar to those strategies used in previous systematic 
review 4 and clinical guidelines update.9 To minimise potential errors, the selection of 
studies and data extraction were performed independently by two reviewers and was also 
compared to data extracted in other systematic reviews.22,23 
Nevertheless, there are many methodological limitations. We restricted our search to 
publications in English language, which could potentially influence the results. However 
other countries use mostly other types of thiazides such as chlorthalidone, metolazone or 
hydrochlorothiazide.54,55,56,57,58 Whilst one study42 was international, other studies 
included in this review were conducted only in the UK.31,33  
We have formally evaluated publication bias, but the number of studies included in this 
review was small. It is possible that some studies, especially earlier studies, were never 
published. We searched clinical trials registers as well as data bases of published 
literature but did not find any more. Although three studies eligible for inclusion had the 
required data available, we could not get access to the original data and therefore could 
not include them in this review.  
There was substantial heterogeneity between the studies included in this review. Firstly, 
hypertension was defined differently between the studies. For example, Hyvet study42 
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considered systolic BP while the other studies31,33 considered diastolic BP.  
Studies measured BP differently, i.e. supine, sitting or standing, and clinic or monitoring 
at home; or one-off measurement or average of measurements from several occasions.  
Inclusion criteria were different between studies. In the HYVET study42 patients were 
previously treated for hypertension but suspended their treatment for at least 2 months 
prior to entry to the study while in the other two trials31,33 the enrolled participants didn’t 
take any medication for hypertension prior to enrollment. 
Participants were recruited from various sources such as general population, medical 
practices and hospitals; therefore, it is difficult to judge the overall generalizability of the 
findings.  
One study31 had follow up of 18 months, while two other studies were long-term follow up 
(over 5 years). However, the results were also available for 2 years follow up in the HYVET 
study 42 and 5.5 years follow up in MRC-TH study.33  In addition, it was possible to estimate 
blood pressure results for one year follow up from graphs in all three studies.  
 
 
Dose information was not available in one study.31  
 
 
 
 
 
Another potential limitation is the fact that some of the trials included a thiazide combined 
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with another drug. For example, in the Hyvet study,42 at 2 years follow-up, 73.4% of the 
active group received both indapamide and perindopril.  
Outcome data were not always complete or were heterogeneous. For example, cause of 
death was missing for some participants in Barraclough.31 This study also withdrew 
controls with diastolic BP>130mmHg but not the active group. There were different 
reasons for medical withdrawals between studies as well as inconsistent reports of non-
medical withdrawals between studies. Additional medication was insufficiently reported 
to allow meaningful data analysis. One study 31 did not report data on systolic BP. Data 
for some parameters, such as standard deviation, were not always available, especially 
in the earlier studies, and therefore assumptions were made using baseline estimates or 
estimates from other studies. This could potentially introduce bias to the overall estimates. 
Quality of the included studies varied, for example one long-term trial 42 and one short-
term trails50 were double-blind. Two studies were large33,42 while the study by 
Barraclaugh31 and three studies of direct comparison were rather small (less than 30).  
All long-term studies and one short-term study reported some form of pharmaceutical 
industry support. However, while the importance of knowledge of who funded a study is 
widely agreed, it was argued that Cochrane risk of bias tool should not include funding 
source as a standard item.59 Conflict of interest in industry-funded trials are likely to 
manifest in selective reporting or problematic choice of comparator. To counteract the 
former, we searched trial registers and, where possible, accessed study protocols. To 
counteract the latter, it was suggested that network meta-analysis can be used for head-
to-head drug comparisons where placebo comparators were used 59, which was used in 
this review. 
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There are several potential methodological problems associated with indirect 
comparison.60 While the combined sample size of the included studies was large, the 
number of studies available for this review was small. Methods for estimating the effective 
number of trials and effective sample size were proposed, which take into account trial 
count ratio. For trial count ratio 1:2 (for example in this review there were two studies of 
bendroflumethiazide and one study of indapamide), the indirect comparison would require 
6 trials (ratio 2:4) to produce precision equivalent to one head-to head trial.61  
We did not combine indirect and direct evidence as the direct evidence came from small 
short-term trials reporting blood pressure only, while the primary aim of this study was to 
compare long-term cardiovascular outcomes. However, it is reassuring that both direct 
and indirect estimates of effect of the drugs on blood pressure were similar. In addition, 
reduced blood pressure seemed to stabilise after one year follow up.33,42 
We compared bendroflumethiazide and indapamide indirectly via placebo. Placebo 
composition was stated only in one trial31 while other studies stated that placebo was 
essentially a look-alike of the active treatment. While there were studies of direct 
comparison of hydrochlorothiazide versus indapamide and hydrochlorothiazide versus 
placebo4,52, they were not included because these drugs are rarely used in the UK.51  
One of the requirements of indirect meta-analysis is that the population groups are 
comparable. Two studies in this review involved participants below age 80 years 31,33 while 
one study42 was conducted in patients aged over 80 years. One might argue that these 
groups are incomparable. Is there any evidence of differential action of these drugs in 
different age groups? A systematic review of pharmacotherapy for hypertension in adults 
aged 18 to 59 years15 includes seven studies and 17,327 participants, and the MRC TH 
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trial33 which is also included in the current review constituted 84% of the population 
considered. The review demonstrated a small absolute effect to reduce cardiovascular 
mortality and morbidity, no reduction in all-cause mortality and coronary and lack of good 
evidence on withdrawal due to adverse events.  
On the other hand, a systematic review of pharmacotherapy for hypertension in the elderly 
23 included fifteen trials and 24,055 participants of age 60 and over with moderate to severe 
hypertension. The review showed a reduction in all-cause mortality and cardiovascular 
morbidity and mortality, but the decrease in all-cause mortality was limited to persons aged 
60 to 80 years. The process of grading the evidence is subjective, and the issue of grade 
inflation has been highlighted previously.62 In this review evidence was graded either as 
low or moderate, and grading was done by authors’ consensus, to minimise potential 
overestimation. 
Guidance for policy makers in interpreting indirect treatment comparisons and network 
meta-analysis is available,63,64 however our results are unlikely to be used for clinical 
decision-making due to deficiency of evidence. 
In this systematic review, we have determined, from small number of studies, that the 
information on direct comparison between indapamide and bendroflumethiazide is very 
limited and the evidence of superiority of indapamide over bendroflumethiazide on long 
term outcomes is inconclusive. Therefore, there is a clear need for large clinical trials 
directly comparing these two drugs. In fact, there are two ongoing studies. The BISON 
(bendroflumethiazide versus indapamide for primary hypertension: observational) study 
within Clinical Practice Research Datalink (CPRD)65 is designed to compare the effect of 
bendroflumethiazide versus indapamide on risk of cardiovascular outcomes using real 
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world data. The EVIDENCE (Evaluating Diuretics in Normal Care) study is a cluster 
randomised evaluation of hypertension prescribing policy in which GP surgeries have their 
practice drug formularies randomised to either indapamide or Bendroflumethiazide.66  
In summary, we have no good comparative effectiveness data on the two most commonly 
prescribed diuretics for hypertension in the UK. 
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Figure 1. Flow Diagram 
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n= 53 studies); Categories are not 
mutually exclusive: 
- not trial of hypertension (n= 12) 
- follow up < 1 year (n= 22) 
- combination therapy (n= 13) 
- observational study (n= 3) 
- single arm trial (n= 3) 
- not study of bendroflumethiazide or 
indapamide (n= 5) 
- thiazides grouped (n= 4) 
- comparison group not a placebo 
(n=3) 
- data not reported for 
bendroflumethiazide or indapamide 
(n=3) 
Eligible articles 
(n = 16) 
Studies included in quantitative synthesis 
(meta-analysis) 
(n = 3) 
Papers available from 
individual studies 
published before 2008 
(n = 26) 
Studies included in qualitative synthesis 
(n= 3) 
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Table 1. Description of the included studies and study participants 
First author/ 
Publication year/ 
Study name 
Country Study 
size 
Follow up # Age (years) Sex  
N (%) 
females 
Sponsorship 
Barraclough 
1973 
Co-operative 
Randomised 
Controlled Trial 
UK 116 6, 12, 18 
months 
Mean  
Treatment group: 
Men 54.4 
Women 55.7 
 
Placebo: 
Men 55.2 
Women 56.5 
 
Range 45-69 
66 
(57%) 
Drugs were supplied by Glaxo Ltd., Merck Sharp and 
Dohme Ltd., and Roche Products Ltd. 
MRC working 
party 
1985 
MRC-TMH 
UK 17,354 1, 2, 3, 4, 5 
years 
Mean  
Males: 51 (SD 8) 
Females: 53 (SD 7) 
 
 
8,306 
(48%) 
Drugs were supplied by Duncan, Flockhart and Co 
Ltd, Imperial Chemical Industries Ltd, CIBA 
Laboratories and Merck Sharp & Dohme Ltd 
Additional support was also provided by Imperial 
Chemical Industries Ltd and Merck Sharp and 
Dohme Ltd. 
Beckett 
2008 
HYVET 
UK, France, 
Ireland, Finland, 
Belgium, Bulgaria, 
Romania, Poland, 
Russia, China, 
Australia, New 
Zealand, Tunisia 
3,845 1, 2, 3, 4, 5 
years 
Mean 
84 (SD 3) 
Range 80-105 
 
 
2,326 
(60%) 
Supported by grants from the British Heart 
Foundation and 
the Institut de Recherches Internationales Servier  
 
# Follow up time when outcomes of interest were available 
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Table 2. Description of studies by inclusion and exclusion criteria 
First author/ 
Publication 
years/ 
Study name 
Population Definition of hypertension How baseline 
blood pressure 
was measured 
Age inclusion 
criteria 
(years) 
Exclusion criteria 
Barraclough 
1973 
Co-operative 
Randomised 
Controlled 
Trial 
Surveys of 
random 
samples of 
general 
population 
and hospital 
patients 
Diastolic BP 100-120 mm Hg 
Two occasions separated by an 
interval of at least 2 weeks 
Garrow random-
zero 
sphygmomanom
eter after sitting 
for 5 min.  
45-69  Renal or cardiac failure or papilloedema; history of 
cerebrovascular accident or MI within the past 3 
months; any serious or potentially fatal disease or 
disability that would prevent regular attendances or 
which contraindicated hypotensive therapy; receiving 
antihypertensive therapy; evidence that hypertension 
was secondary to a surgically remediable condition. 
MRC working 
party 
1985 
MRC-TMH 
General 
medical 
practice 
clinics 
Diastolic pressure 90-109 mm Hg 
and systolic pressure < 200 mm 
Hg; 
Mean of 4 readings taken on 2 
separate occasions and 
confirmed by the mean of 2 later 
readings 
Hawksley 
random zero 
sphygmomanom
eter and London 
School of 
Hygiene 
sphygmomanom
eter 
35-64  Secondary hypertension; taking antihypertensive 
treatment; normally accepted indications for 
antihypertensive treatment (such as congestive cardiac 
failure present); MI or stroke within the previous 3 
months; presence of angina, intermittent claudication, 
diabetes, gout, bronchial asthma, serious intercurrent 
disease, or pregnancy 
Beckett 
2008 
HYVET 
Patients Sustained systolic BP ≥160 mm 
Hg during 2 months of placebo 
run-in period; BP taken twice after 
sitting for 5 min and on the third 
visit and thereafter twice after 
standing for 2 min; Mean of 2 
sitting SBP readings taken on 2 
separate occasions, 1 month 
apart, between 160 and 199 
mmHg  
Standing SBP≥140 mmHg 
Standard 
mercury 
sphygmomanom
eter or validated 
automatic 
device.  
 ≥80  Known accelerated hypertension, heart failure 
requiring treatment with diuretic or ACE inhibitor, renal 
failure (serum creatinine level > 150 μmol/L), 
haemorrhagic stroke in the previous 6 months, terminal 
illness, known secondary hypertension, gout, clinical 
diagnosis of dementia, contraindication to use of the 
trial medications (a serum potassium level of < 3.5 
mmol/L or > 5.5 mmol/L) and a requirement of nursing 
care, inability to stand up or walk 
BP Blood pressure; MI myocardial infarction    
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Table 3. Description of interventions 
 
First author, 
Publication 
year 
Indapamide Bendroflumethiazide Placebo Propanolol Additional treatment 
Barraclough 
1973 
Co-operative 
Randomised 
Controlled Trial 
- Dose is not specified Calcium lactate - Bendrofluazide group: any combination with 
potassium supplement, methyldopa, or 
debrisoquine (discretion of physician) 
MRC working 
party 
1985 
MRC-TMH 
- 10 mg daily Tablets that looked 
like bendrofluazide 
or tablets that 
looked like 
propranolol 
240 mg daily Methyldopa or guanethidine was added if blood 
pressure did not respond satisfactorily to the 
primary drug. If necessary, one of the primary trial 
drugs was used to supplement the other. Control 
patients whose blood pressure rose to levels at 
which placebo treatment was judged unethical 
were transferred to the corresponding active drug. 
For BP >110 mm Hg diastolic and > 200 mm Hg 
systolic in active treatment group additional 
treatment used on discretion of physician.  
Beckett 
2008 
HYVET 
1.5 mg SR 
daily 
- Matching placebo - At each visit (or at the discretion of the 
investigator), if needed to reach the target blood 
pressure, perindopril (2 mg or 4 mg) or matching 
placebo could be added 
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Table 4. Availability of data on outcomes 
 
Outcome First author/ Publication year/ Study name 
Barraclough 1973; Co-operative 
Randomised Controlled Trial 
MRC working party 1985; MRC-TMH Beckett 2008; HYVET 
Timing of outcome 18 months Mean 5.5 years  Median follow up 1.8 years  
All deaths Yes Yes Yes 
Cardiovascular deaths  Yes (cause of death was unknown 
for some of the participants) 
Yes Yes (Death from fatal stroke, fatal myocardial 
infarction, fatal heart failure and sudden death) 
Non-cardiovascular deaths Yes (cause of death was unknown 
for some of the participants) 
Yes Yes 
Stroke Not reported (Assumed 0) Yes (fatal or non-fatal) Yes (fatal or nonfatal) 
Myocardial infarction Yes (fatal or nonfatal) Yes (Coronary events including sudden death thought to 
be due to a coronary cause, death known to be due to 
myocardial infarction, and non-fatal myocardial 
infarction) 
Yes (fatal or nonfatal) 
Other cardiovascular 
events  
Yes (Pulmonary embolism; 
Cardiac failure) 
Yes (Other cardiovascular events, including deaths due to 
hypertension (ICD 400-404) and to rupture or dissection 
of an aortic aneurysm; death from any other cause) 
Yes 
Any cardiovascular events  Yes Yes (Not necessarily equal to the total of strokes plus 
coronary events because it also includes “other relevant 
deaths” and death due to other cardiovascular causes 
such as ruptured aneurysms) 
Yes (Any cardiovascular event was defined as 
death from cardiovascular causes or stroke, 
myocardial infarction, or heart failure) 
Withdrawals for medical 
reasons # 
Yes (Participants from the control 
group with diastolic BP>130mmHg 
were withdrawn by design; 
geriatric hospital admission in the 
bendroflumethiazide group) 
Yes (Impaired glucose tolerance; Gout; Impotence, 
Raynaud’s phenomenon; Skin disorder; Dyspnoea; 
Lethargy; Nausea, dizziness, headache; BP at levels 
requiring change of treatment) 
Yes (Were withdrawn by investigator; Had a 
protocol withdrawal event and no open follow-up) 
Withdrawals for non-
medical reasons 
Yes (Defaulted or non-cooperative) No Yes (centres closed by data monitoring 
committee; had other administrative reasons; 
declined to participate; lost to follow-up) 
Additional medication No additional medication in 
control group by design; All 
participants in the active group 
had additional medication 
Not reported for placebo Yes 
Blood pressure Yes Yes Yes 
# not including primary outcomes;  
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Table 5. Assessment of risk of bias  
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Barraclough 
1973 
Co-operative 
Randomised 
Controlled Trial 
+ - - + - - ? 
MRC working party 
1985 
MRC-TMH 
+ + - + - + ? 
Beckett 
2008 
HYVET 
? + + + + - ? 
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Table 6. Grading the evidence: primary outcomes 
 
Quality assessment № of patients Effect Quality Importance  
№ of 
studies 
Study design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Indapamide 
Bendro- 
flumethiazide 
Relative 
(95% CI) 
 
All deaths (follow up: range 1.5 – 5.5 years) 
3  randomised trials not 
serious  
not serious  very serious  not serious  none  1933 4355 RR 0.82 
(0.57 to 1.18)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Cardiovascular deaths (follow up: range 2-5.5 years) 
2  randomised trials not 
serious  
not serious  very serious  not serious  none  1933 4297 RR 0.82 
(0.56 to 1.20)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Non-cardiovascular deaths (follow up: range 2-5.5 years) 
2  randomised trials not 
serious  
not serious  very serious  not serious  none  1933 4297 RR 0.81 
(0.54 to 1.22)  
⨁⨁◯◯ 
LOW  
CRITICAL 
Stroke (follow up: range 2-5.5 years) 
2  randomised trials not 
serious  
not serious  very serious  not serious  none  1933 4297 RR 2.21 
(1.19 to 4.11)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Coronary events (follow up: range 1.5-5.5 years) 
3  randomised trials not 
serious 
not serious  very serious  not serious  none  1933 4355 RR 0.73 
(0.30 to 1.79)  
⨁⨁◯◯ 
LOW  
CRITICAL 
All cardiovascular events (follow up: range 2-5.5 years) 
2  randomised trials not 
serious  
not serious  very serious  not serious  none  1933 4297 RR 0.89 
(0.67 to 1.18)  
⨁⨁◯◯ 
LOW 
IMPORTANT  
CI: Confidence interval; RR: Risk ratio   
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Table 7. Grading the evidence: secondary outcomes  
 
Quality assessment № of patients Effect 
Quality Importance № of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Indapamide 
Bendro- 
flumethiazide 
Absolute 
(95% CI) 
Systolic blood pressure mmHg (follow up: 1 year) 
2  randomised 
trials 
not 
serious  
not serious  serious  not serious  none  1933 4297 0.94 
(-1.45, 2.25)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL 
Diastolic blood pressure mmHg (follow up: 1 year) 
3  randomised 
trials 
not 
serious  
not serious  serious  not serious  none  1933 4355 0.88 
(-0.19, 1.95)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL 
Systolic blood pressure mmHg (follow up: range 12 - 24 weeks) 
3  randomised 
trials 
serious  not serious  not serious  serious  none  29 27 -0.26 
(-0.79, 0.27)  
⨁⨁◯◯ 
LOW  
IMPORTANT 
Diastolic blood pressure mmHg (follow up: range 12 - 24 weeks) 
3  randomised 
trials 
serious  not serious  not serious  serious  none  29 27  -0.40 (-0.93, 0.14) ⨁⨁◯◯ 
LOW  
IMPORTANT 
CI: Confidence interval 
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Appendix 1. Results by type of outcome  
Number of events 
by type of 
outcome 
Barraclough 1973 Co-operative 
Randomised Controlled Trial 
MRC working party 1985 MRC-TMH Beckett 2008 HYVET 
Indirect comparison 
indapamide vs 
bendroflumethiazide 
RR (95% CI)  * 
Treatment group 
Bendro- 
flumethiazid
e 
N=58 
Placebo 
N=58 
RR (95% CI)  
* 
Bendro- 
flumethiazide 
N=4,297 
Placebo 
N=8,654 
RR (95% CI)  
* Indapamide 
N=1,933 
Placebo 
N=1,912 
RR (95% CI)  
* 
All deaths 1 3 
0.33 
(0.04, 3.11) 
128 253 
1.02 
(0.82, 1.26) 
196 235 
0.82 
(0.69, 0.99) 
0.82 (0.57, 1.18) 
Cardiovascular 
deaths 
- - 
- 
69 139 
0.99 
(0.75, 1.33) 99 121 
0.81 
(0.63, 1.05) 
0.82 (0.56, 1.20) 
Non-
cardiovascular 
deaths 
- - 
- 
59 114 
1.04 
(0.76, 1.42) 97 114 
0.84 
(0.65, 1.10) 
0.81 (0.54, 1.22) 
Stroke 0 0 
- 
18 109 
0.33 
(0.20, 0.55) 
51 69 
0.73 
(0.51, 1.04) 
2.21 (1.19, 4.11) 
Coronary events 1 2 
0.5 
(0.05, 5.36) 
119 234 
1.02 
(0.82, 1.27) 
9 12 
0.74 
(0.31, 1.76) 
0.73 (0.30, 1.79) 
All cardiovascular 
events 
- - 
- 
140 352 
0.80 
(0.66, 0.97) 
138 193 
0.71 
(0.57, 0.87) 
0.89 (0.67, 1.18) 
Withdrawals for 
medical reasons  
1 9 
0.11 
(0.01, 0.85) 
481 1215 
0.80 
(0.72, 0.88) 
4 5 
0.79 
(0.21, 2.94) 
- 
Withdrawals for 
non-medical 
reasons 
10 9 
1.11 
(0.49, 2.53) 0 0 
- 
647 656 
0.98  
(0.89, 1.07) 
- 
Systolic blood 
pressure mmHg 
*** 
- - 
- 
-25.2 (16.1) ** 
-13 
(17.9)** 
-12.20 
(-13.00, -
11.40) # 
-25.7 
(16.5)** 
-13.9 
(18.9)** 
-11.80 (-
13.47, -
10.13) # 
0.94 (-1.45, 2.25) # 
Diastolic blood 
pressure mmHg 
*** 
-20 (9.9)** -5 (12)** 
-15.00 (-
21.61, -
8.39)# 
-12 (9.9)** -6 (12)** 
-6.00 (-6.51, 
-5.49)# 
-11.8 
(10.3)** 
-6.6 
(10.9)** 
-5.20 (-6.20, 
-4.20)# 
0.88 (-0.19, 1.95) # 
* unless otherwise specified ** Mean (SD)   # Mean difference (95% CI)   *** Change from baseline    
29 
 
Appendix 2. Forest plots for long term outcomes 
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All deaths
Bendroflumethiazide vs. Placebo
Indapamide vs. Placebo
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Cardiovascular deaths
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MRC-TMH 1985
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Non-cardiovascular deaths
Bendroflumethiazide vs. Placebo
Indapamide vs. Placebo
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Log RR and 95% CI
Coronary events/MI
Bendroflumethiazide vs. Placebo
Indapamide vs. Placebo
Barraclough 1973
MRC-TMH 1985
HYVET 2008
-5 -4 -3 -2 -1 0 1 2 3 4 5
Log RR and 95% CI
Stroke
Bendroflumethiazide vs. Placebo
Indapamide vs. Placebo
MRC-TMH 1985
HYVET 2008
-5 -4 -3 -2 -1 0 1 2 3 4 5
Log RR and 95% CI
All cardiovascular events
Bendroflumethiazide vs. Placebo
Indapamide vs. Placebo
MRC-TMH 1985
HYVET 2008
-15 0 1
Mean difference and 95% CI
Systolic BP
Bendroflumethiazide vs. Placebo
Indapamide vs. Placebo
Barraclough 1973
MRC-TMH 1985
HYVET 2008
-15 0 1
Mean difference and 95% CI
Diastolic BP
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Appendix 3. Network pattern 
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Appendix 4. Description of studies of direct comparison between indapamide and 
bendroflumethiazie (short term outcome) 
Study characteristic First author/ Publication year/ # 
Bing 1981 Zacharias 1981 Milia 2006 
Population # Hospital 
(Hypertension Clinic) 
No information Cerebrovascular clinic 
Inclusion criteria Mild essential 
hypertension (defined 
as diastolic BP 
≥95mmHg) 
Patients treated with 
atenolol 100 or 200 
mg/day as their sole 
anti-hypertensive 
therapy for at least 8 
weeks 
Ambulant patients with 
first-ever minor 
hemispheric ischemic 
stroke or transient 
ischaemic attack (TIA) 
with or without 
hypertension status 
Exclusion criteria Clinical gout, 
abnormal renal 
function (judged by 
blood urea and serum 
creatinine) 
Cardiac, renal or 
hepatic failure, known 
sensitivity to thiazide 
diuretics or pregnant 
Significant post stroke 
disability (Barthel score 
<70), comorbidity or 
contraindication to 
antihypertensive 
treatment; pre-existing 
moderate to severe renal 
impairment (serum 
creatinine >200 mmol/L) 
or with ≥50% stenosis of 
either carotid artery, BP 
> 180/100 mmHg 
Definition of 
hypertension 
Mild essential 
hypertension (DBP 
≥95 mmHg) 
Hypertension not 
adequately controlled 
on atenolol alone 
No information 
 
How BP was 
measured 
Ascultatory method; 
supine and upright 
position 
Hawksley Random Zero 
Sphygmomanometer; 
supine and upright 
position 
Critikon Dinamap 
equipment (mean of 3 
measurements); supine 
position 
Sponsorship 
 
Servier Laboratories No information No information 
Follow up 16 weeks on single 
drug, followed by 16 
weeks of combined 
therapy 
(indapamide+bendrofl
umethiazide) 
12 weeks 28 days 
Age (years) 32-64  No information 68.8 ±10.6  
Sex N (%) females 10 (50) 9 (53) 13 (50) 
Indapamide 2.5 mg daily 2.5 mg + placebo-
bendroflumethiazide 5 
mg 
2.5 mg daily 
Bendroflumethiazide 5.0 mg daily 5 mg + placebo-
indapamide 2.5 mg 
2.5 mg daily 
Study size 
Indapamide 
Bendroflumethiazide 
20 
10 
10 
17 
No information 
No information 
26 
13 
13 
 
# All studies were conducted in the UK 
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Appendix 5. Assessment of risk of bias  
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Bing 1981 - - - - - - ? 
Zacharias 1981 - + - - - - ? 
Milia P 2006 - - + - - - ? 
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Appendix 6. Results for short-term blood pressure (studies of direct comparison) 
 
Study characteristic 
First author/ Publication year/ # 
Bing 1981 
16 weeks follow up 
Zacharias 1981 
12 weeks follow up 
Milia 2006 
Group size (per 
protocol) 
Indapamide 
Bendroflumethiazide 
 
 
8 
7 
 
 
Assumed 8 
Assumed 8  
 
 
13 
12 
Withdrawals for 
medical reasons 
Indapamide 
 
Bendroflumethiazide 
 
 
1 (dizziness) 
 
3 (1 dizziness; 2 
uncontrolled 
hypertension) 
 
 
1 (at 20 weeks due 
to depression) 
0 
 
 
0 
 
1 (viral illness) 
Withdrawals for non-
medical reasons 
Indapamide 
 
 
Bendroflumethiazide 
 
 
1 (failed to complete 
the study) 
 
0 
 
 
0 
 
 
0 
 
 
0 
 
 
0 
Systolic blood 
pressure, supine 
(mmHg) 
Indapamide 
Baseline Mean (SD) 
Mean change from 
baseline (SD) 
Bendroflumethiazide 
Baseline Mean (SD) 
Mean change from 
baseline (SD) 
 
 
 
No information 
-20.2 (19.9) 
 
 
 
No information 
-14.1 (19.9) 
 
 
 
172 
-15 * 
 
 
 
181 
-22 * 
 
 
 
145 (15.5) 
-14.7 (12.5) 
 
 
 
134.8 (19.3) 
-7.7 (9.16) 
Diastolic blood 
pressure, supine 
(mmHg) 
Indapamide 
Baseline Mean (SD) 
Mean change from 
baseline (SD) 
Bendroflumethiazide 
Baseline Mean (SD) 
Mean change from 
baseline (SD) 
 
 
 
No information 
-6.4 (6.9) * 
 
 
No information 
-3.7 (6.9) *  
 
 
 
101 
-10 
 
 
104 
-11 
 
 
 
78.3 (7.4)  
-7.8 (5.7) * 
 
 
73.4 (10.4)  
-3.67 (4.9) * 
Author’s conclusion Indapamide produced 
a significant but 
equivalent fall in blood 
pressure to that 
observed with 
bendroflumethiazide 
Both drugs produced 
a similar modest 
improvement in 
blood pressure 
Both diuretics reduced 
blood pressure to a 
similar and significant 
degree 
 
* Estimated from information in the paper 
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Appendix 7. Forest plot (short term outcome, studies of direct comparison) 
 
 
 
  
Systolic
Bing 1981
Zacharias 1981
Milia 2006
Subtotal  (I-squared = 13.4%, p = 0.315)
Diastolic
Bing 1981
Zacharias 1981
Milia 2006
Subtotal  (I-squared = 0.0%, p = 0.369)
ID
Study
-0.31 (-1.33, 0.71)
0.35 (-0.64, 1.34)
-0.63 (-1.44, 0.17)
-0.26 (-0.79, 0.27)
-0.39 (-1.42, 0.63)
0.14 (-0.84, 1.13)
-0.77 (-1.59, 0.04)
-0.40 (-0.93, 0.14)
SMD (95% CI)
8, -20.2 (19.9)
8, -15 (19.9)
13, -14.7 (12.5)
29
8, -6.4 (6.9)
8, -10 (6.9)
13, -7.8 (5.7)
29
(SD); Treatment
N, mean
7, -14.1 (19.9)
8, -22 (19.9)
12, -7.7 (9.16)
27
7, -3.7 (6.9)
8, -11 (6.9)
12, -3.67 (4.9)
27
(SD); Control
N, mean
Favours indapamide  Favours bendroflumethiazide 
0-1.59 1.59
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Appendix 8. Funnel plots for long-term outcomes (all deaths and coronary events) and short-term 
outcomes (blood pressure) 
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